Breaking News

Frontage Labs to Expand CMC Facility

June 3, 2014

To increase CMC workforce, capacity by more than 50%

Frontage Labs plans to expand its chemistry, manufacturing and controls (CMC) facility in Exton, PA, including significant capacity to existing services, as well as additional room for future growth.  
 
The initial phase renovation will include two analytical labs and 8000 sq.-ft. of office space, and is scheduled to be complete by the end of September.  The second phase includes additional clinical trial manufacturing (CTM) space for solid, semi-solid and sterile pharma products, packaging, labeling and distribution functions, and will be implemented at the beginning of 2015. Once the expansion is complete, the company expects to increase its CMC workforce and capacity by more than 50%. 
 
“We’re excited that consistent growth over recent years is enabling us to expand capacity and service offerings,” said Dongmei Wang, Senior Vice President of CMC Services. “The infrastructure improvements will allow us to meet ever-thriving client demand for product development support, while adding efficiency gains to small scale CTM production and laboratory throughput.”
 
Frontage’s CMC service portfolio includes organic synthesis, formulation development, GMP analytical testing and GMP clinical trial material manufacturing, for all types of drug candidates ranging from novel, early phase projects to generic-equivalent and consumer care medications. Over the last ten years, Frontage developed oral solid, semi-solid, liquid and sterile dosage forms that have been evaluated in clinical research programs and commercialized in the US, EU and Asian markets by its clients.

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Critical Steps for Biosimilar Assessment

    Critical Steps for Biosimilar Assessment

    Fiona Greer, SGS||May 5, 2016
    Establishing “finger-print like” biosimilarity prior to the clinic